Accepting applications until August 1
Accepting applications until August 1
The current method of BRCA testing for breast and ovarian cancer prevention, which is based on family history, often fails to identify many carriers of pathogenic variants. Population-based genetic testing offers a transformative... Read More
Alexandre Bolze, Elizabeth T. Cirulli, Catherine Hajek,. JAMA Oncol. 2024;10(2):236-239
Genetic information is not being used to identify women at lower risk of breast cancer or other diseases in clinical practice. With the new US Preventive Services Task Force guidelines lowering the age for mammogram screening for... Read More
Isabelle Bedrosian, Mark R. Somerfield, Maria Isabel Achatz, et al. J. Clin Oncol 2024 Feb 10;42(5):584-604
An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. Forty-seven articles met eligibility criteria for the germline mutation testing recomm... Read More
Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, et al.J Clin Oncol. 2025 Feb 20;43(6):682-693
As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome seque... Read More
Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz,et al. Nat Rev Clin Oncol 2026 Feb 18.
Anti-PD-L1 antibodies have transformed cancer treatment and are increasingly being used in patients with early-stage malignancies including in the adjuvant and neoadjuvant settings. In this Review, we explore the optimal use of an... Read More
Suzanne L Topalian, Patrick M Forde, Leisha A Emens,et al. Cancer Cell. 2023 Sep 11;41(9):1551-1566
Among new treatment approaches for patients with cancer, few have accelerated as quickly as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is administered before curative-intent surgery in treatment-naïve... Read More
Andrea Cercek, Michael B Foote, Benoit Rousseau, et al. N Engl J Med. 2025 Jun 19;392(23):2297-2308
Among patients with mismatch repair-deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all e... Read More
Christian U Blank, Minke W Lucas, Richard A Scolyer, et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708
In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. A total of 423 patients underwent randomization. At a median follow-up of... Read More
Yixin Zhou, Anlin Li, Hui Yu, et al. JAMA Netw Open. 2024 Mar 4;7(3):e241285
Neoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates amon... Read More
Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Chinese Medical Journal 2024;137(21)
Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases... Read More
Xin Zhang, Jing Zou, Jinghua Ning,et al. Sci Rep. 2025 Feb 20;15(1):6264
Tracheal, bronchial, and lung cancer (TBL) is among the most common malignancies worldwide, with persistently high incidence and mortality rates, posing a significant threat to public health. This study comprehensively evaluated t... Read More
ML. Meyer, S. Peters, PA Jänne, TS Mok. Et al. ESMO Open. 2026 Feb;11(2):106034
Over the past decade, lung cancer management has been reshaped by advances in early detection, treatment, and prevention. Prevention now extends beyond tobacco control to include recognition of non-tobacco risk factors, screening,... Read More